Indegene DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.76×0.76×0.75×0.73×
1.06×1.07×1.19×1.07×
12.4%14.0%16.0%16.6%
0.88×0.88×0.97×1.02×
1.40×1.47×1.27×1.78×
12.2%14.8%17.7%23.6%
13.9%13.9%20.1%24.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDGN₹593.45

Indegene Ltd.

· Pharma & Health
₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹14,272 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.730.750.760.76
Interest Burden (Pretax/EBIT) ×1.071.191.071.06
EBIT Margin %16.5815.9914.0312.37
Asset Turnover ×1.020.970.880.88
Financial Leverage (Assets/Equity) ×1.781.271.471.40
ROE (5-step product, year-end total equity) %23.6217.6714.8012.24
ROE (owners' profit / average owners' equity) %24.1120.1113.9413.94
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.